Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

Table 2 Adverse events during the pirfenidone and nintedanib administration periods

	During the pirfenidone administration period (n = 30)				During the nintedanib administration period (n = 30)
	Subjects	CTCAE grade			Subjects	CTCAE grade
	Subjects	1	2	3	Subjects	1	2	3
Gastrointestinal
Anorexia	19 (63.3%)	3	14	2	14 (46.7%)	3	8	3
Weight loss	17 (56.7%)	10	5	2	6 (20.0%)	3	3	0
Diarrhea	0	0	0	0	14 (46.7%)	6	7	1
Dyspepsia	5 (16.7%)	1	4	0	0	0	0	0
Nausea	0	0	0	0	2 (6.7%)	0	2	0
Vomiting	0	0	0	0	2 (6.7%)	2	0	0
Other
AST/ALT elevation	1 (3.3%)	0	0	1	19 (63.3%)	12	5	2
Fatigue	5 (16.7%)	1	4	0	3 (10.0%)	1	1	1
Photosensitivity	3 (10.0%)	2	0	1	0	0	0	0
Rash	2 (6.7%)	2	0	0	0	0	0	0
Abdominal pain	0	0	0	0	3 (10.0%)	2	1	0
Back pain	2 (6.7%)	0	2	0	0	0	0	0
Non-cardiac chest pain	1 (3.3%)	1	0	0	0	0	0	0
Fever	0	0	0	0	2 (6.7%)	2	0	0
Acute exacerbation	0	0	0	0	2 (6.7%)	0	0	2

Categorical data are presented as numbers (percentages)
Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase, CTCAE Common Terminology Criteria for Adverse Events

ISSN: 1471-2466